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EFFECTS OF HIV AND DRUGS OF ABUSE ON THE BLOOD-BRAIN BARRIER          
Gopika Hari, MaryPeace McRae
Virginia Commonwealth University, School of Pharmacy
INTRODUCTION
Despite effective systemic therapy, HIV-1 infection
within the brain results in neuronal degradation
and neurocognitive dysfunction. This
neurocognitive dysfunction is worsened in the
setting of opiate abuse. The central nervous
system (CNS) is protected by the blood-brain
barrier (BBB), a selective barrier regulating the
passage of substances from peripheral circulation
into the CNS. The BBB is composed of
microvascular endothelial cells encased by basal
lamina, pericytes, and perivascular astrocyte
endfeet. Intracellular junctional complexes
comprising of adherens and tight junctions are
located between the endothelial cells and form
tight barrier, preventing traffic of compounds
between cells (paracellular flux). Clinical and in
vitro data suggest that BBB integrity is
compromised in HIV infection, which leads to a
leaky barrier. Brain microvascular endothelial
cells also express efflux transporters that are
responsible for the extrusion of substances from
the brain back into the blood. P-glycoprotein is a
drug efflux transporter involved in the efflux of
many antiretroviral drugs and overexpression of
P-glycoprotein can limit therapeutic
concentrations of substrate drugs within the
brain. Additionally, P-glycoprotein expression
and/or function may be altered in the setting of
HIV infection and in the setting of drug abuse.
Lavríková P, Fontana J. Functions of Cells and Human Body, Chapter 12.11, 2014.
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OBJECTIVES
The purpose of this study was to analyze the
impact of HIV-1 Tat and morphine on P-
glycoprotein (Pgp) as a means to study the impact
of substance abuse drugs on drug-efflux proteins
in the BBB. This will be done by:
Analyzing Pgp function through Rhodamine-123
cellular accumulation studies
Analyzing Pgp expression through Western Blots
P-glycoprotein Western Blots 
Experiment 
#1 Rhodamine-123 Accumulation
RESULTS
Well with cells
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Cells washed and florescence measured
PGP
Inside of hCMEC/D3 cell
Protein expression of P-glycoprotein was measured by
immunoblot analysis. Pgp expression was significantly
decreased in all treatment groups as compared to
control; Tat (63±4.2%, p< 0.05), morphine (64±13.5%,
p<0.05) and Tat+morphine (69± 15.6%, p<0.05).
Compared to control, statistically significant increases in cellular
accumulation of rhodamine-123 were observed in both the
morphine (mean±SEM; 118± 6.5%, p<0.05) and Tat+morphine
(118 ± 13.1%, p<0.05) groups. Increased Rh-123 accumulation
indicates decreased P-glycoprotein function due to less substrate
being effluxed from the interior of the cell.
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Areas for further study include:
• Analysis of Tat and morphine on other drug
efflux proteins, such as breast cancer
resistance protein (BCRP) and the multidrug
resistance proteins (MRPx).
• Intracellular accumulation of drugs used in
the treatment of HIV ( such as atazanavir or
lopinavir) would allow for analysis of the
impact of P-glycoprotein in efflux of
antiretroviral therapy drugs.
Increase in accumulation of Rhodamine-123
within cells treated with Tat, morphine, and
Tat+morphine treatment groups indicate
decreased ability of P-glycoprotein to efflux
substrates out of the cell. This is
complemented with decreased expression of
the P-glycoprotein protein in endothelial cell
membranes under each of the treatment
groups. Both experiments indicate increased
leakiness of the BBB when exposed to HIV-1
protein and opioids. This has implications in
both determining substances that lead to
increased BBB breakdown and factors that
lead to increased permeability of cells to
antiretroviral therapy drugs.
The effects of Tat and morphine on Pgp protein expression
were measured by immunoblot. Gels were run in an
electrophoresis box and protein was transferred to the
membrane using a wet transfer. Blots were then blocked
with milk and probed for both P-glycoprotein and beta-actin
(to provide controls for each sample). C219 (1:200 dilution)
was used for Pgp primary antibody, and anti-beta actin
(1:4000 dilution) was used for beta-actin primary. Both
samples used anti-mouse HRP-linked substrate (1:20000
dilution) for secondary antibodies.
In order to study the impact of morphine, a commonly used
opiate drug of abuse, on drug-efflux proteins at the BBB, the
effects of morphine and the HIV-1 protein Tat on P-glycoprotein
function were studied via intracellular accumulation studies.
hCMEC/D3 cells, a human derived brain microvascular
endothelial cell line, were pre-treated for 24h with Tat (100nM),
morphine (500nM), or Tat (100nM) + morphine (500nM). 12-
well plates with 3 replicates of each treatment group were used.
Accumulation was determined by measuring florescence from
the prototypical P-glycoprotein substrate, rhodamine-123,
following cell lysis.
Extracellular space
= florescent Rhodamine-123
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